Pancreatitis Trial, Recruiting NCT05694988 Sponsor: Efferon JSC Condition: Pancreatitis
Back to Pancreatitis

Pancreatitis Trial, Recruiting

NCT05694988
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • You have been diagnosed with acute pancreatitis (a sudden inflammation of the pancreas) with no signs of infection, confirmed using the Atlanta classification guidelines from 2012
  • Your pancreatitis has been confirmed by a CT scan, and your CT severity score is 4 points or higher on the Modified CTSI scale (confirm with trial site)
  • Your pancreatitis attack started no more than 3 days ago
  • Your illness severity score (called APACHE II) is at least 10 points, meaning your condition is considered serious enough (confirm with trial site)
  • You are already receiving adequate fluid treatment (at least 30 ml per kg of body weight) from the time you enter the trial
  • Your condition is stable enough to receive treatment for at least 4 hours

Who may not be able to join:

  • You are older than 75 years
  • Your pancreatitis attack started more than 3 days ago
  • Your current pancreatitis is a flare-up of long-term (chronic) pancreatitis
  • Your pancreatitis developed as a complication of a surgical procedure
  • You are in septic shock (a life-threatening response to infection)
  • You have an untreated surgical infection somewhere in your body
  • You have a high score on a scale measuring other serious health conditions you already have (Charlson index above 5 points) (confirm with trial site)
  • Your blood oxygen levels are critically low (confirm with trial site)
  • Your level of consciousness is significantly reduced, as measured by a standard scale (GCS below 12) (confirm with trial site)
  • You have severe obesity, weighing more than 150 kg
  • Your blood fat (triglyceride) levels are very high — over 1000 mg/dl
  • You have dementia
  • Your blood pressure cannot be kept at a safe level even with medication and fluids over 24 hours
  • You have end-stage kidney disease that requires dialysis or a similar treatment
  • You have advanced liver cirrhosis (scarring of the liver), scoring more than 5 on the Child-Pugh scale (confirm with trial site)
  • You have an unresolved blockage in your bile ducts
  • You have recently been diagnosed with a blood clot in your lungs (pulmonary embolism), confirmed by a CT scan
  • You have had a heart attack within the last 4 weeks
  • You have recently had a stroke
  • You have had a serious reaction to a blood transfusion
  • You have severe heart failure
  • You have active, uncontrolled bleeding in the last 24 hours

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Makariy Mendibaev, MD, Demikhov City Clinical Hospital of the Moscow Health Department

Phone: +79636564765

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Efferon JSC
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
30 January 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Effect of the combined use of the Efferon CT device and HVHF on indicators of organ dysfunction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov